1-20 of 106
D Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

CME
Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis
Journal: Blood
Blood (2024) 144 (25): 2637–2651.
https://doi.org/10.1182/blood.2024026212
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Luca Paruzzo, Riemke Bouvier, Guido Ghilardi, Eugenio Fardella, Bria Fulmer, Ivan J Cohen, Elise A. Chong, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Vrutti Patel, Li Ziyu, Raymone Pajarillo, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Stefan K. Barta, Patrizia Porazzi, Joseph A. Fraietta, Vijay Bhoj, Alfred L. Garfall, Edward A. Stadtmauer, Stephen J. Schuster, Jordan S. Carter, Sokratis A. Apostolidis, Sandra Susanibar-Adaniya, Marco Ruella
Journal: Blood
Blood (2024) 144 (Supplement 1): 7243.
https://doi.org/10.1182/blood-2024-206608
Published: 2024
Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Sarah Girgis, Leonard Finnaca, Samantha Le, Sara Whittington, George Mellgard, Connor B Grady, Zachary Wolfe, Adam F. Binder, Rajshekhar Chakraborty, Christopher Strouse, Hira Shaikh, Shivani Kapur, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall
Journal: Blood
Blood (2024) 144 (Supplement 1): 3381.1.
https://doi.org/10.1182/blood-2024-199411
Published: 2024
Journal Articles

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Chau Nguyen, Cynthia Diaczynsky, Inna Strakovsky, Eva Bondesson, Helen Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra Susanibar-Adaniya, Adam Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer
Journal: Blood
Blood (2024) 144 (Supplement 1): 7060.
https://doi.org/10.1182/blood-2024-204155
Published: 2024
Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella
Journal: Blood
Blood (2024) 144 (Supplement 1): 3779.
https://doi.org/10.1182/blood-2024-206544
Published: 2024
Journal Articles

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Zainul S. Hasanali, Alfred L. Garfall, Dan T. Vogl, Sandra Susanibar-Adaniya, Adam D. Cohen, Edward A. Stadtmauer, Shivani Kapur, Adam Waxman, David Allman
Journal: Blood
Blood (2024) 144 (Supplement 1): 3266.
https://doi.org/10.1182/blood-2024-209100
Published: 2024
Journal Articles

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Adam D. Cohen, Sandra Susanibar-Adaniya, Oksana De Mesa, Alfred L. Garfall, Dan T. Vogl, Adam Waxman, Shivani Kapur, E Paul Wileyto, Anjana Nair, Zainul S. Hasanali, Lauren Karpf, Edward A. Stadtmauer
Journal: Blood
Blood (2024) 144 (Supplement 1): 3373.
https://doi.org/10.1182/blood-2024-203635
Published: 2024
Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Benjamin F. Frost, Olga Shestova, Sara Sleiman, Brandon Simone, Feng Shen, Miroslaw Kozlowski, Michelle Wang, J. Joseph Melenhorst, Noelle Frey, Elizabeth O. Hexner, Megan M. Davis, Joseph A. Fraietta, Avery Gaymon, Rong Xu, Chia Sharpe, John C. Byrd, Mark O'Hara, Adam D. Cohen, Stephen J. Schuster, Donald L. Seigel, Carl H. June, David L. Porter, Saar Gill
Journal: Blood
Blood (2024) 144 (Supplement 1): 909.
https://doi.org/10.1182/blood-2024-202659
Published: 2024
Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Y Krishnan, Jacob P. Laubach, Adam D. Cohen, Suzanne Trudel, Luciano J. Costa, Nizar J. Bahlis, Peter A. Forsberg, Rayan Kaedbey, Rafael Fonseca, Andrew Spencer, Paula Rodríguez-Otero, Maria-Victoria Mateos, Chihunt Wong, James Cooper, Tulika Tyagi, Rin Nakamura, Voleak Choeurng, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2024-199542
Published: 2024
Journal Articles

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Carolyn Y. Fang, Jakub Svoboda, Adam D. Cohen, Henry C. Fung, Richard I. Fisher, Elizabeth Handorf, Hatcher Ballard, Stefan K. Barta, Daniel J. Landsburg, Dwivedy S. Nasta, Stephen J Schuster, Rashmi Khanal, Alexander W. MacFarlane, Kerry S. Campbell
Journal: Blood
Blood (2023) 142 (Supplement 1): 6526.
https://doi.org/10.1182/blood-2023-189330
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, Oxana Megherea, Adam Waxman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2035.
https://doi.org/10.1182/blood-2023-189277
Published: 2023
Journal Articles

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Mia Djulbegovic, Meredith Doherty, Katie Fanslau, Kan Chen, Sarah Girgis, Pearl Joslyn, Shawn Carney, Joyce Mitchell, Abbie Etzweiler, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra Susanibar-Adaniya, Zachary AK Frosch, Qi Long, Karen Glanz, Edward A. Stadtmauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 909.
https://doi.org/10.1182/blood-2023-174451
Published: 2023
Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3389.
https://doi.org/10.1182/blood-2023-187409
Published: 2023
Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Hamza Hassan, Mehmet K. Samur, Adam D. Cohen, Philippe Moreau, Paula Rodríguez Otero, Shaji Kunnathu Kumar, María Victoria Mateos, David Avigan, Adam S. Sperling, Omar Nadeem, Michael Hudecek, Carlos Fernández de Larrea, Joaquin Martínez-López, Maria Themeli, Kwee Yong, Jesus G. Berdeja, Ajai Chari, Pieter Sonneveld, Francesca Gay, Amrita Krishnan, Saad Z Usmani, Kenneth C. Anderson, Sundar Jagannath, Hermann Einsele, Nikhil C Munshi, Shonali Midha
Journal: Blood
Blood (2023) 142 (Supplement 1): 7248.
https://doi.org/10.1182/blood-2023-184710
Published: 2023
Journal Articles

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Connor Grady, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall
Journal: Blood
Blood (2023) 142 (Supplement 1): 3394.
https://doi.org/10.1182/blood-2023-177735
Published: 2023
Journal Articles

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

Rocio Montes de Oca, Junchen Gu, Hao Zhao, Kathy Zelinsky, Dianna Wu, Cuc Davis, Jaymala Patel, Brad Foulk, Rengasamy Boominathan, Onsay Lau, Denis Smirnov, Yi Lin, Sundar Jagannath, Adam D. Cohen, Nahor Haddish-Berhane, Jean Xu, Deepu Madduri, An-Sofie Stevens, Carolyn Chang Jackson, Jordan M. Schecter, Arnob Banerjee, Dong Geng, Jieqing Zhu, Sifan Xu, Enrique Zudaire
Journal: Blood
Blood (2023) 142 (Supplement 1): 2099.
https://doi.org/10.1182/blood-2023-182298
Published: 2023
Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Clinical Trials & Observations
Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini
Journal: Blood
Blood (2023) 142 (14): 1208–1218.
https://doi.org/10.1182/blood.2022019406
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022